AbstractBySubCategory

Clinical Trials

Immune Checkpoints and Stimulatory Receptors

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010. Matthew David Hellmann

77

Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12). Alain Patrick Algazi

78

Avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma: Subgroup analysis of efficacy. Howard L. Kaufman

80

Tremelimumab: A monoclonal antibody against CTLA-4—In combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC). Austin G. Duffy

88

Model-based meta-analysis of safety for immune checkpoint inhibitor combinations and monotherapy. Kald Abdallah

89

Single-center experience with nivolumab in pretreated patients with non-small cell lung cancer (NSCLC). Bernardo Leon Rapoport

90

Experience of immune-related adverse events associated with ipilimumab and nivolumab in a single center. Bernardo Leon Rapoport

91

Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea. Keunchil Park

92

Incidence and average cost per toxicity in patients treated with nivolumab. Neil Thomas Mason

93

Correlation of PD-L1 with VEGF and KI-67 index in patients with primary glioma. Song Xue

94

Preliminary results from a single-arm, phase II study assessing the efficacy of pembrolizumab plus radiotherapy in metastatic triple negative breast cancer. Alice Ho

95

Preliminary results from a phase II study of nivolumab for patients with metastatic adrenocortical carcinoma (ACC). Ludimila Cavalcante

96